Penggunaan Antihipertensi pada Penderita Penyakit Paru Obstruktif Kronis

Oleh :

dr. Hendra Gunawan SpPD

Penggunaan antihipertensi pada pasien penyakit paru obstruktif kronis (PPOK) harus dilakukan dengan baik agar tidak menimbulkan eksaserbasi. PPOK dilaporkan telah diderita oleh lebih dari 175 juta jiwa di seluruh dunia, menurut studi Global Burden of Disease pada tahun 2015. Angka ini diduga akan semakin meningkat seiring dengan bertambahnya jumlah penduduk yang merokok, dan meningkatnya populasi usia lanjut.[1,2]

Kaitan Hipertensi dan PPOK

Salah satu penyakit penyerta dari PPOK adalah hipertensi, sesuai dengan laporan dari The Global Initiative for Chronic Obstructive Lung Disease (GOLD) pada tahun 2017. Studi cross sectional dari Hye et al melaporkan bahwa PPOK memiliki asosiasi terhadap hipertensi secara independen.[3,4]

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Yılmaz İ. Angiotensin-Converting Enzyme Inhibitors Induce Cough. Turk Thorac J. 2019;20(1):36-42.
2. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691-706.
3.Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med. 2017;195(5):557-82.
4.Kim S-H, Park J-H, Lee J-K, Heo EY, Kim DK, Chung HS. Chronic obstructive pulmonary disease is independently associated with hypertension in men: A survey design analysis using nationwide survey data. Medicine. 2017;96(19):e6826.
5.Kunisaki KM, Dransfield MT, Anderson JA, Brook RD, Calverley PMA, Celli BR, et al. Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial. Am J Respir Crit Care Med. 2018;198(1):51-7.
6.Kjeldsen SE. Hypertension and cardiovascular risk: General aspects. Pharmacol Res. 2018;129:95-9.
7.Finks SW, Rumbak MJ, Self TH. Treating Hypertension in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine. 2020;382(4):353-63.
8.Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13-e115.
9.Herrin MA, Feemster LC, Crothers K, Uman JE, Bryson CL, Au DH. Combination antihypertensive therapy among patients with COPD. Chest. 2013;143(5):1312-20.
10.Di Daniele N. Therapeutic approaches of uncomplicated arterial hypertension in patients with COPD. Pulm Pharmacol Ther. 2015;35:1-7.
11.Vozoris NT, Wang X, Austin PC, O'Donnell DE, Aaron SD, To TM, et al. Incident diuretic drug use and adverse respiratory events among older adults with chronic obstructive pulmonary disease. Br J Clin Pharmacol. 2018;84(3):579-89.
12.Mancini GBJ, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary Disease. Journal of the American College of Cardiology. 2006;47(12):2554-60.
13.Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1 Suppl):169s-73s.
14.Lipworth B, Skinner D, Devereux G, Thomas V, Ling Zhi Jie J, Martin J, et al. Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease. Heart. 2016;102(23):1909-14.
15.Morales DR, Lipworth BJ, Donnan PT, Jackson C, Guthrie B. Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study. BMC Medicine. 2017;15(1):18.
16.Angeloni E, Melina G, Roscitano A, Refice S, Capuano F, Lechiancole A, et al. β-Blockers improve survival of patients with chronic obstructive pulmonary disease after coronary artery bypass grafting. Ann Thorac Surg. 2013;95(2):525-31.
17.Andersson C, Hansen PW, Steffensen IE, Andreasen C, Weeke PE, Køber L, et al. Mortality associated with cardiovascular drugs in patients with chronic obstructive pulmonary disease and right-sided heart failure - A danish nationwide registry-based study. Eur J Intern Med. 2019;63:56-61.
18.Biernacki W, Flenley DC. Doxazosin, a new alpha-1-antagonist drug, controls hypertension without causing airways obstruction in asthma and COPD. J Hum Hypertens. 1989;3(6):419-25.
19. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, et al. 2023 ESH Guidelines For The Management Of Arterial Hypertension The Task Force For The Management Of Arterial Hypertension Of The European Society Of Hypertension Endorsed By The International Society Of Hypertension (ISH) And The European Renal Association (ERA). J Hypertens. 2023. Doi: 10.1097/HJH.0000000000003480. https://journals.lww.com/jhypertension/fulltext/2023/12000/2023_esh_guidelines_for_the_management_of_arterial.2.aspx